BIOMAT Database Logo BIOMAT Database Logo

[Drug therapy for chronic polyarthritis]. 1977

K Grasedyck

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D010396 Penicillamine 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease. Dimethylcysteine,Mercaptovaline,beta,beta-Dimethylcysteine,Copper Penicillaminate,Cuprenil,Cuprimine,D-3-Mercaptovaline,D-Penicillamine,Metalcaptase,D 3 Mercaptovaline,D Penicillamine,Penicillaminate, Copper,beta,beta Dimethylcysteine
D002738 Chloroquine The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses. Aralen,Arechine,Arequin,Chingamin,Chlorochin,Chloroquine Sulfate,Chloroquine Sulphate,Khingamin,Nivaquine,Sulfate, Chloroquine,Sulphate, Chloroquine
D006046 Gold A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis

Related Publications

K Grasedyck
[Drug therapy of chronic polyarthritis].
August 1966, Medizinische Klinik,
K Grasedyck
[Drug therapy of progressive chronic polyarthritis].
October 1968, Die Medizinische Welt,
K Grasedyck
[Drug therapy of progressive chronic polyarthritis].
August 1972, Therapeutische Umschau. Revue therapeutique,
K Grasedyck
[Drug therapy of juvenile chronic polyarthritis].
May 1980, Fortschritte der Medizin,
K Grasedyck
[Therapy of chronic polyarthritis. 1. Causal therapy, basic drug therapy].
August 1972, Fortschritte der Medizin,
K Grasedyck
[Current status of drug therapy in chronic polyarthritis].
September 1991, Therapeutische Umschau. Revue therapeutique,
K Grasedyck
[Drug and physical therapy of primary chronic polyarthritis].
April 1972, Medizinische Klinik,
K Grasedyck
[On long term drug therapy of primary chronic polyarthritis].
September 1967, Die Medizinische Welt,
K Grasedyck
For the therapy of chronic polyarthritis.
March 1959, Wiener medizinische Wochenschrift (1946),
K Grasedyck
[Long-term course of chronic polyarthritis under basic drug therapy].
March 1988, Deutsche medizinische Wochenschrift (1946),
Copied contents to your clipboard!